160 related articles for article (PubMed ID: 32764831)
1. CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Matsuoka H; Ando K; Swayze EJ; Unan EC; Mathew J; Hu Q; Tsuda Y; Nakashima Y; Saeki H; Oki E; Bharti AK; Mori M
PLoS One; 2020; 15(8):e0228002. PubMed ID: 32764831
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.
Ando K; Shah AK; Sachdev V; Kleinstiver BP; Taylor-Parker J; Welch MM; Hu Y; Salgia R; White FM; Parvin JD; Ozonoff A; Rameh LE; Joung JK; Bharti AK
Oncotarget; 2017 Jul; 8(27):43733-43751. PubMed ID: 28415827
[TBL] [Abstract][Full Text] [Related]
3. Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.
Ando K; Tohme YH; Srinivasiah A; Taylor-Parker J; Harrington Y; Shah AK; Oki E; Brahmandam M; Bharti AK
J Histochem Cytochem; 2018 Aug; 66(8):549-561. PubMed ID: 29587004
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan.
Meisenberg C; Ashour ME; El-Shafie L; Liao C; Hodgson A; Pilborough A; Khurram SA; Downs JA; Ward SE; El-Khamisy SF
Nucleic Acids Res; 2017 Feb; 45(3):1159-1176. PubMed ID: 28180300
[TBL] [Abstract][Full Text] [Related]
5. Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
Ando K; Ozonoff A; Lee SY; Voisine M; Parker JT; Nakanishi R; Nishimura S; Yang J; Grace Z; Tran B; Diefenbach TJ; Maehara Y; Yasui H; Irino T; Salgia R; Terashima M; Gibbs P; Ramanathan RK; Oki E; Mori M; Kulke M; Hartshorn K; Bharti A
Clin Colorectal Cancer; 2021 Jun; 20(2):e129-e138. PubMed ID: 33731288
[TBL] [Abstract][Full Text] [Related]
6. Resistance to TOP-1 Inhibitors: Good Old Drugs Still Can Surprise Us.
Kumar S; Sherman MY
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108395
[TBL] [Abstract][Full Text] [Related]
7. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
[TBL] [Abstract][Full Text] [Related]
8. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
[TBL] [Abstract][Full Text] [Related]
9. Distinct Mechanism Evolved for Mycobacterial RNA Polymerase and Topoisomerase I Protein-Protein Interaction.
Banda S; Cao N; Tse-Dinh YC
J Mol Biol; 2017 Sep; 429(19):2931-2942. PubMed ID: 28843989
[TBL] [Abstract][Full Text] [Related]
10. Next generation topoisomerase I inhibitors: Rationale and biomarker strategies.
Teicher BA
Biochem Pharmacol; 2008 Mar; 75(6):1262-71. PubMed ID: 18061144
[TBL] [Abstract][Full Text] [Related]
11. Personalized Drug Efficacy Monitoring Chip.
Velasco V; Joshi K; Chen J; Esfandyarpour R
Anal Chem; 2019 Dec; 91(23):14927-14935. PubMed ID: 31710202
[TBL] [Abstract][Full Text] [Related]
12. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
[TBL] [Abstract][Full Text] [Related]
13. Activity of Topotecan toward the DNA/Topoisomerase I Complex: A Theoretical Rationalization.
Bali SK; Marion A; Ugur I; Dikmenli AK; Catak S; Aviyente V
Biochemistry; 2018 Mar; 57(9):1542-1551. PubMed ID: 29412654
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Stewart AJ; Mistry P; Dangerfield W; Bootle D; Baker M; Kofler B; Okiji S; Baguley BC; Denny WA; Charlton PA
Anticancer Drugs; 2001 Apr; 12(4):359-67. PubMed ID: 11335793
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T; Maitra R; Zhang J; Nayak J; Goel S
Invest New Drugs; 2019 Oct; 37(5):948-960. PubMed ID: 30612311
[TBL] [Abstract][Full Text] [Related]
16. Functional mismatch repair and inactive p53 drive sensitization of colorectal cancer cells to irinotecan via the IAP antagonist BV6.
Tomicic MT; Steigerwald C; Rasenberger B; Brozovic A; Christmann M
Arch Toxicol; 2019 Aug; 93(8):2265-2277. PubMed ID: 31289894
[TBL] [Abstract][Full Text] [Related]
17. DNA-PKcs interference sensitizes colorectal cancer cells to a mTOR kinase inhibitor WAY-600.
Wu L; Zhang J; Wu H; Han E
Biochem Biophys Res Commun; 2015 Oct; 466(3):547-53. PubMed ID: 26381179
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Braun AH; Stark K; Dirsch O; Hilger RA; Seeber S; Vanhoefer U
Anticancer Drugs; 2005 Nov; 16(10):1099-108. PubMed ID: 16222152
[TBL] [Abstract][Full Text] [Related]
19. Drug Resistance of CPT-11 in Human DLD-1 Colorectal Cancer Cells through MutS Homolog 2 Upregulation.
Lee KC; Yen CK; Chen CN; Chang SF; Lu YC; Huang WS
Int J Med Sci; 2021; 18(5):1269-1276. PubMed ID: 33526988
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide mapping of Topoisomerase I activity sites reveal its role in chromosome segregation.
Rani P; Nagaraja V
Nucleic Acids Res; 2019 Feb; 47(3):1416-1427. PubMed ID: 30566665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
